Mental Health

AIIMS to start Web Portal on Mental health care (MiHOPE) from 10th October. This portal will be helpful for online consultations where patients can discuss about mental health-related problems with the health professional and wellness experts. AIIMS has also started the Mental Health Access Summit 2020, which is a semi-online program that started from 4th to 11th October. The theme of submit is “Mental Health for All-Greater Investment- Greater Access”, the program was inaugurated Dr. Randeep Guleria, Director, AIIMS, New Delhi.

“During COVID time the general access to health care and especially mental health care is massively impacted and hampered. The majority of the mental health issues are treatable just like other physical illnesses. However, unlike availing treatment for physical conditions, we fail to seek help for our emotional problem.” says Dr. Nand Kumar, Professor of the Psychiatry dept, AIIMS

The Medical Council of India (MCI) has denied permission to Idukki Medical college on 25September for admitting students. The letter sent by MCI to Medical college has mentioned about seven points as a reason for not giving permission to the Idukki Medical college for admissions. The medical college has deficiencies like residents (58%) , faculty(18%) clinical lab ,Bed occupancy (29.3%)  and radiological investigation.

In report board of governors has also mentioned about the condition of hospital building which is old and used as Medical college and no approach road to the hospital.

It was the last chance for the medical college for admitting MBBS students. The Medical Council of India (MCI)has not done any physical verification due to COVID-19.

Hyderabad-based Bharat Biotech who is one of the leading vaccine candidates has announced will use adjuvant Alhydroxiquim-II which will boost immunity response and longer-lasting immunity. The technology is being used under this licensing agreement with Kansas-based ViroVax LLC.

Bharat Biotech is currently conducting Phase II human trials of COVAXIN after receiving approval from the Drug Controller General of India (DCGI).

“There is critical need for development and availability of adjuvants that elucidate mechanisms of action inducing greater antibody responses to vaccine antigens, thus resulting in long-term protection against pathogens. Adjuvants also enhance the sustainability of the global vaccine supply on account of their antigen-sparing effect. Our partnership with ViroVax resonates with Bharat Biotech’s relentless efforts towards developing safe and effective vaccines coupled with long term immunity.”says Dr Krishna Ella, Chairman and Managing Director ,Bharat Biotech

“The widely used adjuvant Aluminium hydroxide in the development of SARS CoV-2 vaccines is known to induce a Th2 based response (which are important for eradication of extracellular parasites and bacterial infection). The Th2 based response has a theoretical risk of vaccine associated enhanced respiratory diseases (VAERD or ADE). We have used Imidazoquinoline class of adjuvants (TLR7/8 agonists), which are known to induce Th1 based response which further reduces the risk of ADE (Anti-Body Dependent Enhancement). Dr Krishna Ella Further added

India has recorded 66,23,816 confirmed COVID-19 cases in 24hours , 903 deaths with a spike of 74,442 new cases in a single day. Total no.of deaths till date are 1,02,685.

Maharashtra , Andhra Pradesh and Karnataka are the states who reported maximum no.of cases.But rise in infection rate in states like Uttar Pradesh , Tamil Nadu and West Bengal . India’s recovery rate is higher than before 84.3 percent .

Maharashtra has maximum no.of cases till now

Maharashtra: 14,43,409
Andhra Pradesh: 7,19,256
Karnataka: 6,40,661
Tamil Nadu: 6,19,996
Uttar Pradesh: 4,14,466

Total testing done till now

According to the Indian Council of Medical Research (ICMR) total no.of samples were tested on October 4 are 9,89,860, a total of 7,99,82,394 samples tested till October 4.

A total of 7,99,82,394 samples tested for #COVID19 up to October 4. Of these, 9,89,860 samples were tested yesterday: Indian Council of Medical Research (ICMR)

Union Health Minister Harsh Vardhan during Sunday Samvaad said “States given time upto end-Oct to submit lists of priority population groups for receiving COVID-19 vaccine, where priority shall be given to health workers. We expect to receive & utilise 400-500 million doses & cover approx 20-25 crore people by July 2021.”

On Russia’s vaccine SPUTNIKV during Sunday Samvaad ,Union Minister of Health and Family Welfare Dr Harsh Vardhan said “No final decision on SPUTNIKV vaccine developed by Russia has been taken yet. Central government will take a decision which is in the best interest of the people of India.

Indo-Tibetan Border Police organises Yoga session at ITBP-run Sardar Patel COVID Care Centre & Hospital, Radha Soami Satsang Beas in Delhi’s Chhatarpur.

ITBP -run COVID Care Centre currently has more than 1200 COVID-19 patients admitted, 5500 patients discharged so far.

Delhi is recording more than two thousand cases daily.The number of patients hospitalized has been declined over past ten days in Delhi